Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor
AssigneeBoard of Regents, The University of Texas System
InventorsRegino Perez-Polo, Olivera Nesic
Life of this patent
Estimating the term…
Abstract
The present invention concerns the use of interleukin-1 receptor antagonists for the treatment of spinal cord injuries (SCI). IL-1ra may be administered to a patient with a spinal cord injury in an effective amount. Such methods also include combination therapies in which IL-1ra is administered in addition to other therapeutic agents for the treatment of SCI.
Claims46
A method of treating spinal cord injury in which the spinal cord is not completely severed in a subject comprising administering a therapeutically effective amount of IL-1 receptor antagonist (IL-1ra) to the site of injury.
A method of treating a spinal cord injury comprising:
- a) identifying a subject in need of such treatment,
- b) identifying the type of spinal cord injury;
- and
- c) administering a therapeutically effective amount of IL-1 receptor antagonist to the site of injury over a therapeutically effective time period.
A pharmaceutical composition for the treatment of spinal cord injury at the site of injury comprising IL-1 receptor antagonist and methylpredisolone.
A pharmaceutical composition for the treatment of spinal cord injury at the site of injury comprising IL-1 receptor antagonist and a neurotrophic factor.
A method of treating spinal cord injury in which the spinal cord is not completely severed in a subject comprising administering a therapeutically effective amount of recombinant human IL-1 receptor antagonist (IL-1ra) to the site of injury.
Dependencies are inferred from the claim text.